rexlemestrocel-l — Clinical data readout
H2 2027
We look forward to reading out the trial's clinical endpoints during the second half of the 2027 calendar year.Source filing
MESO biotech catalysts & pipeline
MESOBLAST LTD · Data as of 2026-10-25
Upcoming catalysts
rexlemestrocel-l — NDA/BLA submission
Q3 CY2027
A positive readout will be used in support of an expected regulatory filing in Q3 CY2027 for United States Food and Drug Administration (FDA) approval.Source filing